(Q36116333)

English

A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

object named as

Selby PJ

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

object named as

Perren TJ

2

0 references

author name string

Joffe JK

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Bradley C

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Primrose J

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Hallam S

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ward U

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Illingworth JM

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

1 January 1997

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

full work available at URL

https://doi.org/10.1038/bjc.1997.69

object of statement has role

published version

0 references

http://eprints.whiterose.ac.uk/100570

content deliverer

White Rose Research Online

object of statement has role

published version

1 reference

White Rose Research Online

15 December 2018

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

75

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

423-426

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 October 2017

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 October 2017

Phase II trial of recombinant beta interferon in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 October 2017

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 October 2017

Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 October 2017

Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 July 2018

Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 July 2018

Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 July 2018

Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 July 2018

Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

2 July 2018

Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

23 September 2018

Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

23 September 2018

Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063373

23 September 2018

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9020490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9020490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9020490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9020490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/9020490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence and structural homologies among type I and type II interferons

1 reference

https://pubmed.ncbi.nlm.nih.gov/9020490

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1997.69

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

10.1038/BJC.1997.69

0 references

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36116333&oldid=2198223484"